Procter & Gamble Health Ltd
Procter & Gamble Health Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Procter & Gamble Health Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8). The provided pages of the investor presentation do not explicitly report EBITDA, operating margin, or quarterly profit (PAT) figures with year-on-year change.
From Procter & Gamble Health Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).
- Profit after tax (PAT) increased by +30% in the same period (Page 8).
- Net Sales showed a +7% CAGR over the past 5 years (Page 27).
- PAT grew at a +13% CAGR over 5 years (Page 27).
- Return on Equity (ROE) increased by 43% over 5 years (Page 27).
- No explicit quarterly revenue or volume numbers are directly provided.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹370 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Procter & Gamble Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q1 FY27 results?
FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8). The provided pages of the investor presentation do not explicitly report EBITDA, operating margin, or quarterly profit (PAT) figures with year-on-year change.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.
Is Procter & Gamble Health Ltd planning capital expenditure?
The provided pages of the presentation do not contain any specific information regarding capex, capacity expansion, new plants, projects, amounts, statuses, or timelines.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.